Recent 8-K filings for CAI

• August 5, 2026, 4:12 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B

  Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.

• June 5, 2026, 5:03 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Caris Life Sciences shareholders elect ten directors, ratify Deloitte as auditor for FY2026

  Annual Meeting held June 4, 2026; 273.7M shares represented (96.8% of 282.7M outstanding).

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M

  Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.

• April 2, 2026, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 1.02item 2.03 ◈ Material Agreements ×2◈ Debt Financings

  Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone

  Borrowed $400M initial term loan to repay existing credit agreement from January 2023.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B

  Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.

• January 12, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%

  Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.

• November 5, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M

  Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).

• October 30, 2025, 7:59 PM ET other material materiality 0.35 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Caris Life Sciences adopts 3% ownership threshold for derivative proceedings

  Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M

  Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.

• June 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  Caris Life Sciences completes IPO of 23.5M shares at $21.00, raising $494.1M gross

  IPO of 23,529,412 shares of common stock at $21.00 per share closed June 20, 2025.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

7 positive 0 negative 3 neutral

source · CAI on sec.gov